VRXAHealthcare · Biotechnology

VRXA Stock Forecast: VERAXA Biotech AG Price Predictions for 2026-2027

Last close, 3 Aug 2026

$1.83

+3.98% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 1 Aug 2026 — in the lower half.

Market cap

$248.9M

Ticker Nerd rank

38 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

−9.0%

−10.3%

YTD

−82.8%

−82.4%

From 52W high

−92.6%

From 52W low

+6.1%

$25

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

VRXA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores VERAXA Biotech AG on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026

38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Volatility

Value

Issuance

Quality

Accruals

Momentum

Revisions

Growth

Size (81): Smaller than most of the companies we track.

Growth (20): Sales and profits are flat, shrinking, or growing more slowly than they were.

The rank is the raw material. Whether the rules would actually own VERAXA Biotech AG — and when they’d sell — is the membership.

Wall Street

VRXA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VRXA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

VRXA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

VERAXA Biotech AG (VRXA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: 10624.0×
Price / book: —
EV / EBITDA: −3.9×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: −286020.0%
Net margin: 66.0%

Returns & dividend

Return on equity: 422.5%
Return on assets: −82.4%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VRXA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
VRXAVERAXA Biotech AG	$248.9M	38
INOInovio Pharmaceuticals, Inc.	$55.5M	50
BOLDBoundless Bio, Inc.	$56.0M	88
CNTXContext Therapeutics, Inc.	$55.1M	43
PMVPPMV Pharmaceuticals, Inc.	$58.8M	66
DWTXDogwood Therapeutics, Inc.	$52.6M	53
INKTMiNK Therapeutics, Inc.	$52.1M	60

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VRXA appears on the weeks it earns a place.

News

Latest VRXA news & analysis

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

GlobeNewsWire · 29 July 2026positive

VERAXA Biotech announced that during the first half of 2026 it filed initial patent applications covering its new BiTAC-TCE and BiTAC-ADC platforms and related therapeutic programs.

Why it matters — Patent filings help protect VERAXA's core technology platforms and product candidates, which could strengthen the company's competitive position as it develops novel cancer therapies.

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

GlobeNewsWire · 27 July 2026positive

VERAXA Biotech's bispecific antibody drug conjugate program VXA-222, developed through a joint discovery collaboration with OmniAb, is advancing into the next phase after a key technical milestone was achieved.

Why it matters — The progression of VXA-222 into the next development phase signals continued pipeline advancement for VERAXA Biotech.

VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth

GlobeNewsWire · 24 July 2026positive

VERAXA Biotech AG held an Extraordinary General Meeting on July 24, 2026, where all resolutions proposed by the Board of Directors were approved by over 99.94% of shareholders present or represented.

Why it matters — The overwhelming shareholder approval strengthens VERAXA's strategic flexibility, which is relevant to VRXA watchers monitoring the company's ability to pursue future growth initiatives.

FAQ

Frequently asked questions about VRXA stock

How does Ticker Nerd's model rank VRXA?

As at 1 Aug 2026, VERAXA Biotech AG ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (81 of 100).

What is the VRXA stock forecast for 2030?

No analyst covering VERAXA Biotech AG publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRXA are extrapolating price history, which says nothing about the business.

How has VRXA stock performed over the past year?

VERAXA Biotech AG returned -82.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does VERAXA Biotech AG do?

What is the latest news on VRXA?

The most recent item we track (GlobeNewsWire, 29 July 2026): "VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates". VERAXA Biotech announced that during the first half of 2026 it filed initial patent applications covering its new BiTAC-TCE and BiTAC-ADC platforms and related therapeutic programs.

Company

About VERAXA Biotech AG.

Veraxa Biotech Holding AG is an oncology-focused biotechnology company that operates Veraxa Biotech AG, a clinical-stage biopharmaceutical business dedicated to antibody-based cancer therapies. The group concentrates on developing novel drug platforms that use engineered antibodies to deliver targeted treatment to solid and hematologic tumors, with a particular emphasis on antibody-drug conjugates and T cell engagers. Central to its approach is the proprietary BiTAC concept, which enables dual-targeting mechanisms designed to improve precision and reduce off‑target effects in cancer therapy. Veraxa Biotech Holding AG leverages advanced microfluidics and genetic code expansion technologies to design, screen, and optimize these next‑generation therapeutics. Headquartered in Zurich, Switzerland, with operations centered around its R&D hub in Heidelberg, Germany, the company plays a specialized role in the global biopharmaceutical market by supplying innovative platforms and clinical candidates to address unmet needs in oncology.

CEO Dr. Christoph Antz Ph.D. · Germany · https://www.veraxa.com